2 slots left meaning
Tooth Filling Materials Market Poised for Tremendous Growth from 2024 to 2032 12-20-2024 06:53 PM CET | Health & Medicine Press release from: Cognate Insights Tooth Filling Materials Market Latest Market Overview The global tooth filling materials market is projected to reach USD 5.1 billion by 2024, expanding at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2032. Tooth filling materials play a critical role in restorative dental procedures, as they are used to restore teeth damaged by cavities or trauma. The market growth is driven by the increasing incidence of dental cavities, growing awareness of oral hygiene, and advancements in dental technologies. Additionally, the rising preference for aesthetic dental procedures, coupled with the availability of durable and cosmetic filling materials, is fueling market expansion. The Tooth Filling Materials Market has experienced steady growth in recent years and is expected to continue expanding at a strong pace from 2024 to 2032. This analysis offers a comprehensive overview, providing valuable insights into key trends and developments within the Tooth Filling Materials industry. These findings equip business leaders with the necessary knowledge to devise more effective strategies and enhance profitability. Furthermore, the report serves as a useful resource for new and emerging businesses, helping them make informed decisions as they navigate the market and seek growth opportunities. Some of the prominent players in the global tooth filling materials market include: 3M (USA) - Revenue: USD 35.1 billion Dentsply Sirona (USA) - Revenue: USD 5.1 billion Ivoclar Vivadent (Liechtenstein) - Revenue: USD 1.3 billion Kerr Corporation (USA) - Revenue: USD 3.5 billion Coltene Holding AG (Switzerland) - Revenue: USD 550 million Get Latest PDF Sample Report @ https://www.cognateinsights.com/request-sample/tooth-filling-materials-market-research Our Report covers global as well as regional markets and provides an in-depth analysis of the overall growth prospects of the market. Global market trend analysis including historical data, estimates to 2024, and compound annual growth rate (CAGR) forecast to 2032 is given based on qualitative and quantitative analysis of the market segments involving economic and non-economic factors. Furthermore, it reveals the comprehensive competitive landscape of the global market, the current and future market prospects of the industry, and the growth opportunities and drivers as well as challenges and constraints in emerging and emerging markets. Global Tooth Filling Materials Market Landscape and Future Pathways: North America: United States Canada Europe: Germany France U.K. Italy Russia Asia-Pacific: China Japan South Korea India Australia China Taiwan Indonesia Thailand Malaysia Latin America: Mexico Brazil Argentina Korea Colombia Middle East & Africa: Turkey Saudi Arabia UAE Korea Speak to Our Analyst for A Discussion on The Above Findings, And Ask for A Discount on The Report @ https://www.cognateinsights.com/check-discount/tooth-filling-materials-market-research Key drivers and challenges influencing the Tooth Filling Materials market: Regional Analysis: The report involves examining the Tooth Filling Materials market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets. Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Tooth Filling Materials market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends. Company Analysis: Report covers individual Tooth Filling Materials manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies. Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Tooth Filling Materials This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application. Technology Analysis: Report covers specific technologies relevant to Tooth Filling Materials. It assesses the current state, advancements, and potential future developments in Tooth Filling Materials areas. Reason to Buy this Report: -Analysis of the impact of technological advancements on the market and the emerging trends shaping the industry in the coming years. -Examination of the regulatory and policy changes affecting the market and the implications of these changes for market participants. -Overview of the competitive landscape in the Tooth Filling Materials market, including profiles of the key players, their market share, and strategies for growth. -Identification of the major challenges facing the market, such as supply chain disruptions, environmental concerns, and changing consumer preferences, and analysis of how these challenges will affect market growth. -Evaluation of the potential of new products and applications in the market, and analysis of the investment opportunities for market participants. For In-Depth Competitive Analysis - Purchase this Report now at @ https://www.cognateinsights.com/purchase-report/tooth-filling-materials-market-research Contact Us: Cognate Insights Web: www.cognateinsights.com Email: info@cognateinsights.com Phone: +91 8424946476 About Us: We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy. This release was published on openPR.ASX set to rise, Wall Street wavers as tech giants slump
20 Autocorrect Jokes That’ll Hope You Leaving in Snitches!‘India And Kuwait Will Become Partners In Prosperity’: PM Modi Tells ‘Mini Hindustan’ At ‘Hala Modi’ Event
Helping to drown out the noiseEAST LANSING, Mich. — The sight was a common one for Andrew Kolpacki. For many a Sunday, he would watch NFL games on TV and see quarterbacks putting their hands on their helmets, desperately trying to hear the play call from the sideline or booth as tens of thousands of fans screamed at the tops of their lungs. When the NCAA's playing rules oversight committee this past spring approved the use of coach-to-player helmet communications in games for the 2024 season, Kolpacki, Michigan State's head football equipment manager, knew the Spartans' QBs and linebackers were going to have a problem. "There had to be some sort of solution," he said. As it turns out, there was. And it was right across the street. Kolpacki reached out to Tamara Reid Bush, a mechanical engineering professor who not only heads the school's Biomechanical Design Research Laboratory but also is a football season ticket-holder. Kolpacki "showed me some photos and said that other teams had just put duct tape inside the (earhole), and he asked me, 'Do you think we can do anything better than duct tape,?" Bush said. "And I said, 'Oh, absolutely.'" Bush and Rylie DuBois, a sophomore biosystems engineering major and undergraduate research assistant at the lab, set out to produce earhole inserts made from polylactic acid, a bio-based plastic, using a 3D printer. Part of the challenge was accounting for the earhole sizes and shapes that vary depending on helmet style. Once the season got underway with a Friday night home game against Florida Atlantic on Aug. 30, the helmets of starting quarterback Aidan Chiles and linebacker Jordan Turner were outfitted with the inserts, which helped mitigate crowd noise. DuBois attended the game, sitting in the student section. "I felt such a strong sense of accomplishment and pride," DuBois said. "And I told all my friends around me about how I designed what they were wearing on the field." All told, Bush and DuBois have produced around 180 sets of the inserts, a number that grew in part due to the variety of helmet designs and colors that are available to be worn by Spartan players any given Saturday. Plus, the engineering folks have been fine-tuning their design throughout the season. Dozens of Bowl Subdivision programs are doing something similar. In many cases, they're getting 3D-printed earhole covers from XO Armor Technologies, which provides on-site, on-demand 3D printing of athletic wearables. The Auburn, Alabama-based company has donated its version of the earhole covers to the equipment managers of programs ranging from Georgia and Clemson to Boise State and Arizona State in the hope the schools would consider doing business with XO Armor in the future, said Jeff Klosterman, vice president of business development. XO Armor first was approached by the Houston Texans at the end of last season about creating something to assist quarterback C.J. Stroud in better hearing play calls delivered to his helmet during road games. XO Armor worked on a solution and had completed one when it received another inquiry: Ohio State, which had heard Michigan State was moving forward with helmet inserts, wondered if XO Armor had anything in the works. "We kind of just did this as a one-off favor to the Texans and honestly didn't forecast it becoming our viral moment in college football," Klosterman said. "We've now got about 60 teams across college football and the NFL wearing our sound-deadening earhole covers every weekend." The rules state that only one player for each team is permitted to be in communication with coaches while on the field. For the Spartans, it's typically Chiles on offense and Turner on defense. Turner prefers to have an insert in both earholes, but Chiles has asked that the insert be used in only one on his helmet. Chiles "likes to be able to feel like he has some sort of outward exposure," Kolpacki said. Exposure is something the sophomore signal-caller from Long Beach, California, had in away games against Michigan and Oregon this season. Michigan Stadium welcomed 110,000-plus fans for the Oct. 26 matchup between the in-state rivals. And while just under 60,000 packed Autzen Stadium in Eugene, Oregon, for the Ducks' 31-10 win over Michigan State three weeks earlier, it was plenty loud. "The Big Ten has some pretty impressive venues," Kolpacki said. "It can be just deafening," he said. "That's what those fans are there for is to create havoc and make it difficult for coaches to get a play call off." Something that is a bit easier to handle thanks to Bush and her team. She called the inserts a "win-win-win" for everyone. "It's exciting for me to work with athletics and the football team," she said. "I think it's really exciting for our students as well to take what they've learned and develop and design something and see it being used and executed." Get local news delivered to your inbox!
Four Canadian women honoured in World Rugby's Dream Teams of the Year MONACO — Canadians Alex Tessier, Sophie de Goede and Laetitia Royer have been named to World Rugby's Women’s 15s Dream Team of the Year. Canada sevens captain Olivia Apps, meanwhile, was selected to World Rugby's Women’s Sevens Dream Team. Canadian Press Nov 27, 2024 2:12 PM Nov 27, 2024 2:35 PM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message France's Marine Menager grabs Canada's Alex Tessier's leg as she runs the ball during WXV 1 women's rugby union action, in Vancouver on Sept. 29, 2024. THE CANADIAN PRESS/Ethan Cairns MONACO — Canadians Alex Tessier, Sophie de Goede and Laetitia Royer have been named to World Rugby's Women’s 15s Dream Team of the Year. Canada sevens captain Olivia Apps, meanwhile, was selected to World Rugby's Women’s Sevens Dream Team. The women's 15s world all-star squad also featured six players from top-ranked England and three from No. 2 New Zealand. The other three came from the U.S., Ireland and France. Tessier was also a finalist for the World Rugby Women’s 15s Player of the Year award won by England fullback Ellie Kildunne. France's Pauline Bourdon Sansus and England's Alex Matthews were the other finalists. Tessier won her 50th cap in 2024 and, playing at inside centre alongside fly half Claire Gallagher, led the Canada women to a historic first-ever victory over New Zealand to win the 2024 Pacific Four Series in May. The 22-19 comeback victory lifted Canada into second place in the women’s world rankings, its highest position since November 2016. Tessier's strong kicking game was also key for Canada. The 31-year-old from Sainte-Clotilde-de-Horton, Que., scored 27 points in starting all six matches for Canada in 2024 to up her career total to 48 points (including five tries) in 54 appearances. Tessier plays professionally in England for the Exeter Chiefs. De Goede made the all-star team despite tearing her anterior cruciate ligament in training in June. A finalist for the Women's Player of the Year award in 2022, the Victoria back-rower plays in England for Saracens. Royer, from Loretteville, Que., is a second-row forward who plays in France for ASM Romagnat. Top-ranked South Africa dominated the men's 15s all-star squad with seven players represented. Ireland had four players with New Zealand three and Argentina one. --- World Rugby's 15s Dream Teams of the Year Women 1. Hope Rogers (U.S.); 2. Georgia Ponsonby (New Zealand); 3. Maud Muir (England); 4. Zoe Aldcroft (England); 5. Laetitia Royer (Canada) ; 6. Aoife Wafer (Ireland)' 7. Sophie de Goede (Canada) ; 8. Alex Matthews (England); 9. Pauline Bourdon Sansus (France); 10. Holly Aitchison (England); 11. Katelyn Vahaakolo (New Zealand); 12. Alex Tessier (Canada) ; 13. Sylvia Brunt (New Zealand); 14. Abby Dow (England); 15. Ellie Kildunne (England). Men 1. Ox Nche (South Africa); 2. Malcolm Marx (South Africa); 3. Tyrel Lomax (New Zealand); 4. Eben Etzebeth (South Africa); 5. Tadhg Beirne (Ireland); 6. Pablo Matera (Argentina); 7. Pieter-Steph du Toit (South Africa); 8. Caelan Doris (Ireland); 9. Jamison Gibson-Park (Ireland); 10. Damian McKenzie (New Zealand); 11. James Lowe (Ireland); 12. Damian de Allende (South Africa); 13. Jesse Kriel (South Africa); 14. Cheslin Kolbe (South Africa); 15. Will Jordan (New Zealand). World Rugby Sevens Dreams Team of the Year Women Olivia Apps (Canada) , Michaela Blyde (New Zealand), Kristi Kirshe (U.S.), Maddison Levi (Australia), Ilona Maher (U.S.), Jorja Miller (New Zealand), Séraphine Okemba (France). Men Selvyn Davids (South Africa), Antoine Dupont (France), Aaron Grandidier Nkanang (France), Terry Kennedy (Ireland), Nathan Lawson (Australia), Ponipate Loganimasi (Fiji), Matías Osadczuk (Argentina). This report by The Canadian Press was first published Nov. 27, 2024. The Canadian Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message More National Sports Hometown favourite Gushue beats Carruthers at Grand Slam's Kioti National Nov 27, 2024 2:13 PM Robert Wickens moving up to IMSA GTD series in 2025 thanks to new Bosch hand controls Nov 27, 2024 2:03 PM RCMP investigating death of Edmonton man after mixed martial arts fight Nov 27, 2024 1:14 PM Featured Flyer
NonePresident-elect Donald Trump's transition team says several of his political allies were "targeted in violent, un-American threats to their lives." Trump himself has been the target of assassination attempts. The US Federal Bureau of Investigation (FBI) on Wednesday said that it is looking into a series of threats against members of President-elect Donald Trump 's new Cabinet. "The FBI is aware of numerous bomb threats and swatting incidents targeting incoming administration nominees and appointees," adding that agents were "working with our law enforcement partners" on the case. Trump transition team spokeswoman Karoline Leavitt had raised the alarm earlier on Wednesday. "Last night and this morning, several of President Trump's Cabinet nominees and appointees were targeted in violent, un-American threats to their lives and those who live with them," she said. Leavitt said Trump allies were the targets of bomb threats as well as so-called "swatting attacks" — a reference to people reporting a fabricated serious crime in a bid to trigger a large emergency law enforcement operation at someone's home or workplace . Trump has been announcing his nominations and picks for various Cabinet posts in recent days and weeks, amid preparations for his inauguration on January 20. US President-elect Trump's controversial cabinet picks To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video js/msh (AP, Reuters)Four Canadian women honoured in World Rugby's Dream Teams of the Year
Oncology Information System Market Entry Strategies And Marketing Channels and Forecast To 2031 | McKesson Corporation, Siemens Healthineers, Elekta AB 11-21-2024 08:43 PM CET | Health & Medicine Press release from: DataM Intelligence 4 Market Research LLP DataM Intelligence The latest report on Oncology Information System Market offers valuable insights into emerging trends and pivotal developments within the market. It highlights significant growth opportunities that market participants can leverage, alongside strategic recommendations for capitalizing on these trends. This report serves as an indispensable tool for stakeholders seeking to deepen their understanding of the market landscape and identify actionable pathways for growth. By utilizing this in-depth analysis, stakeholders will gain the insights necessary to effectively adapt to shifting market conditions and strengthen their competitive position. Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/oncology-information-system-market Oncology Information Systems (OIS) play a critical role in managing and streamlining data for cancer patient care. These systems are designed to handle a wide range of functions, including patient hospitalization records, treatment plans, diagnostic results, and treatment delivery documentation. By centralizing and organizing this data, OIS improve the efficiency and accuracy of cancer treatment processes across various healthcare departments. Key features of OIS include the ability to integrate with hospital information systems, enabling seamless data sharing and communication between different departments, such as radiology, pathology, and oncology. This integration is essential for the evaluation and improvement of treatment protocols, as it ensures that healthcare providers have access to real-time, comprehensive information on a patient's cancer stage, treatment history, and progress. OIS also contribute to medical safety and clinical effectiveness by reducing the risk of errors, supporting treatment personalization, and enhancing decision-making. By enabling clinicians to easily access and track treatment outcomes, OIS help improve patient care and ensure that treatments are continuously optimized based on the latest data. Moreover, the system supports data retention through both digital and paper-based methods, such as hospital registries, ensuring that patient information is securely maintained and accessible for future evaluations. As healthcare systems continue to prioritize digital transformation, the role of OIS in improving cancer care management is expected to expand, further enhancing treatment outcomes and patient safety. Market Dynamics The increasing global incidence of cancer is indeed a primary driver for the growth of the Oncology Information Systems (OIS) market. As cancer cases continue to rise worldwide, there is a growing need for effective management systems to streamline patient data, treatment plans, and clinical processes. The significant surge in cancer diagnoses, as reported by Globocan 2020 and the International Agency for Research on Cancer, highlights the pressing need for advanced data management tools like OIS, which enable healthcare providers to track and manage the growing volume of cancer cases efficiently. In particular, the aging global population is contributing to a higher prevalence of cancer, further increasing the demand for oncology-focused healthcare systems. OIS can assist in managing the complexity of care for elderly patients, who often require more comprehensive and long-term treatment plans. Moreover, as the oncology pipeline expands, with more cancer treatments being developed and progressing through late-stage clinical trials, OIS play a crucial role in maintaining accurate records of these treatments and ensuring that they are integrated into patient care plans. By supporting the exchange of information between healthcare providers, researchers, and patients, OIS help ensure that the latest treatment options are easily accessible and that clinical outcomes are continuously monitored and optimized. This combination of factors-rising cancer incidence, an aging population, and the growing number of new cancer treatments-is expected to drive substantial growth in the OIS market over the coming years, as these systems become integral to managing cancer care and improving treatment outcomes globally. Key Developments: In September 2020, Siemens Healthineers entered into a definitive agreement to acquire Varian Medical Systems. This acquisition will strengthen the company's existing portfolio of oncology information systems List of the Key Players in the Oncology Information System Market: Koninklijke Philips N.V., Varian Medical Systems Bayer, McKesson Corporation, Siemens Healthineers, Elekta AB, Epic Systems Corporation, IBM, Cerner Corporation, Advanced-Data Systems, Bogardus Medical Systems, Inc. Research Process: Both primary and secondary data sources have been used in the global Oncology Information System Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges. Segment Covered in the Oncology Information System Market: By Product & Services (Software, Services) By Application (Radiation Oncology, Medical Oncology, Surgical Oncology) By End User (Hospitals & Diagnostic Imaging Centers, Government Institutions, Ambulatory Surgical Centers, Research Facilities) Regional Outlook: The global Oncology Information System Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa. Get Customization in the report as per your requirements+Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/oncology-information-system-market Regional Analysis: The global Oncology Information System Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Oncology Information System Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications. **The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted** Points Covered: ⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Oncology Information System market segments, study objectives, and years considered. ⏩ Market Landscape: The competition in the Global Oncology Information System Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies. ⏩ Companies Profiles: The global Oncology Information System market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production. ⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study. ⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Oncology Information System Market. ⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type. ⏩ Research Findings: This section of the report showcases the findings and analysis of the report. ⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided. Unlock Year-End Savings! Get Up to 30% Off: https://www.datamintelligence.com/buy-now-page?report=oncology-information-system-market Frequently Asked Questions ● What is the expected growth rate of the global Oncology Information System market for the forecast period? ● What are the key driving factors that are responsible to shape the fate of the Oncology Information System market during the forecast period? ● What will be the overall size of the market during the analysis period? ● What are the prominent market trends which influence the development of the Oncology Information System market across various regions? ● Who are the key market players and the market strategies that have helped them to secure the leading position in the global Oncology Information System market? ● What are the challenges and threats that are likely to act as a barrier to the growth of the Oncology Information System market? ● What are the major opportunities that the companies can get to attain success in the world? Contact Us - Company Name: DataM Intelligence Contact Person: Sai Kiran Email: Sai.k@datamintelligence.com Phone: +1 877 441 4866 Website: https://www.datamintelligence.com About Us - DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele. This release was published on openPR.
Stocks wavered in afternoon trading, as losses for several Big Tech companies offset gains elsewhere in the market. The S&P 500 fell 0.5 per cent, even though more stocks were rising than falling in the index. The Dow Jones fell 78 points, or 0.2 per cent. Both indexes set records on Tuesday. The Nasdaq composite fell 1.1 per cent. Wall Street’s tech giants retreated on Wednesday. Credit: AP The Australian sharemarket is set to inch up, with futures at 4.56am AEDT pointing to a rise of 14 points, or 0.1 per cent, at the open. The ASX added 0.6 per cent on Wednesday. Losses for tech heavyweights helped pull the broader market lower. Semiconductor giant Nvidia slipped 3.3 per cent. Its huge value gives it outsized influence on market indexes. Microsoft fell 1.1 per cent. Several personal computer makers added to Big Tech’s heavy weight on the market following their latest earnings reports. Loading HP sank 12.6 per cent after giving investors a weaker-than-expected earnings forecast for its current quarter. Dell slumped 12.1 per cent after its latest quarterly revenue fell short of Wall Street forecasts. Gains for financial and health care companies helped counter Big Tech’s downward pull. The US economy expanded at a healthy 2.8 per cent annual pace from July through September, according to the Commerce Department, leaving its original estimate of third-quarter growth unchanged. The growth was driven by strong consumer spending and a surge in exports.Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
None
(Reuters) - U.S. President-elect Donald Trump and French President Emmanuel Macron shared an intense series of handshakes on Saturday, reminiscent of the white-knuckled grip-off that marked a meeting between the two leaders more than seven years ago. Visiting Paris to attend the reopening of the Notre-Dame cathedral, Trump was greeted by Macron at the steps of the Elysee Palace. It was Trump's first foreign trip since winning the Nov. 5 U.S. election. Exiting his vehicle, Trump pulled Macron's right hand towards his body as the two hugged and gripped each other with clenched fists, shaking firmly back and forth. While friendly, it appeared both men were holding on tight. As they ascended the steps of the palace and turned again towards the cameras, Trump positioned his hand above Macron's and pushed down firmly as they locked hands for a second time. The sequence triggered approval from some Trump supporters online, who saw in the president-elect's actions a concerted attempt to intimidate Macron. "President Trump is back to dominating world leaders with his handshake," an account who goes by the username @BehizyTweets posted on the social media platform X. "Macron is going to need a hand massage after all that twisting and pulling Trump did to him." The two men have a history of intense handshakes. When they met for the first time in May 2017 ahead of a NATO summit in Brussels, each man gripped each other's right hand so firmly that their knuckles turned white and their jaws seemed to clench as they sat for a face-to-face meeting. Macron told a newspaper in 2017 that the white-knuckle handshake was "not innocent" and "a moment of truth" aimed at showing his U.S. counterpart, whose first term ended in January 2021, that he would not be intimidated. Trump and Macron were joined later on Saturday by Ukraine's President Volodymyr Zelenskiy. The meeting occurred with world leaders in Paris to celebrate Notre-Dame's restoration five years after it was ravaged by fire. Trump and Macron shared another firm and prolonged handshake outside the cathedral, though it fell short of the intensity of the 2017 grip-off, according to social media influencer Collin Rugg. "The handshake battle between Donald Trump and Emmanuel Macron continues," Rugg posted on X. "Their handshake at the Notre Dame Cathedral lasted for 17 seconds, coming short of their previous record of 29 seconds." (Reporting by Nathan Layne in New York; Editing by Paul Simao)
AMHERST, Mass. (AP) — Quinton Mincey had 27 points in UMass-Lowell's 96-83 victory over UMass on Saturday. Mincey added six rebounds for the River Hawks (6-4). Martin Somerville scored 22 points and added five assists. Yuri Covington had 19 points and shot 5 of 9 from the field, including 2 for 5 from 3-point range, and went 7 for 8 from the line. Jayden Ndjigue led the way for the Minutemen (3-7) with 17 points, eight rebounds, five assists and two steals. Jaylen Curry added 17 points and two steals for UMass. Marqui Worthy finished with 15 points. UMass-Lowell took a 17-13 lead in the first half with a 10-0 run. Led by 12 first-half points from Covington, UMass-Lowell carried a 40-38 lead into the break. UMass-Lowell took the lead for what would be the final time on Xzavier Lino's jump shot with 15:41 left in the contest. His team would outscore UMass by 11 points in the final half. Story continues below video UMass-Lowell plays Wednesday against LIU at home, and UMass hosts UMass-Boston on Saturday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenHelping to drown out the noise